We have several clinical studies ongoing and planned with our MultiTAA T-cell product candidates. Target indications include acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and breast cancer.

Based on positive results of MultiTAA product candidates in various blood and solid tumor cancers, we are pursuing acute myeloid leukemia as our lead indication with the goal of broadening patient treatment options. We are currently enrolling patients in the safety lead-in portion of our multicenter randomized Phase 2 AML study. See clinical trials below: